Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2693]

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA

MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )

Zamtocabtagene autoleucel improves event-free survival vs standard of care in...

Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL ( Prof Peter Borchmann - University Hospital of Cologne, Cologne, Germany )

Anitocabtagene autoleucel achieves deep and durable responses in relapsed...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

$Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )$

Talquetamab plus teclistamab shows promise in true extramedullary multiple...

Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma ( Dr Shahzad Raza - Cleveland Clinic, Cleveland, USA )

AI and pathology reveal higher late recurrence risk in invasive lobular breast...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting...

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )

Empowering cancer care in Africa

Prof Cesaltina Ferreira Lorenzoni - Mozambican Ministry of Health, Maputo...

Empowering cancer care in Africa ( Prof Cesaltina Ferreira Lorenzoni - Mozambican Ministry of Health, Maputo, Mozambique and AORTIC President )

Do all hormone sensitive prostate cancers need triplet therapy?

Dr Deepak Dabkara - Tata Medical Center, Kolkata, India

Do all hormone sensitive prostate cancers need triplet therapy? ( Dr Deepak Dabkara - Tata Medical Center, Kolkata, India )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

Prof Thomas Powles - Barts Cancer Institute, London, UK

ctDNA-guided adjuvant atezolizumab improves OS in MIBC ( Prof Thomas Powles - Barts Cancer Institute, London, UK )

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for...

Dr Scott Tagawa - Weill Cornell Medicine, New York, USA

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC ( Dr Scott Tagawa - Weill Cornell Medicine, New York, USA )

More from ecancer